Updates
** Drug developer Mineralys Therapeutics' MLYS.O shares rise as much as 73% to a near two-year high of $18.19
** Stock set for biggest percentage gain in a day on record
** MLYS says its experimental drug, lorundrostat, met the main goals of mid- and late-stage trials
** In the late-stage trial, co's drug reduced blood pressure by 9.1 mmHg (millimeters of mercury) at 6 weeks, compared with placebo
** Lorundrostat inhibits production of aldosterone, a hormone that can contribute to high blood pressure
** In the mid-stage trial, the drug reduced blood pressure by placebo-adjusted 7.9 mmHg
** Brokerage Guggenheim hailed the data as a major win for the drug, saying it could become a "potent first-in-class and (a) potential best-in-class agent"
** Stock has fallen 24.7% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。